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Abstract 
BACKGROUND: Glial Fibrillary Acidic Protein (GFAP) is a protein produced by astrocytes in response to brain 
injury, which then penetrates the cerebrospinal fluid and the blood stream.  
AIM: We sought to determine whether GFAP serum level in acute ischemic stroke could predict clinical outcome. 
METHODS: As much as 64 patients with first-ever ischemic stroke had their GFAP serum level measured at 72 
hours after onset. The National Institute of Health Stroke Scale (NIHSS) was assessed during the 72 hours of 
onset, the seventh day, and followed up 1 month after. 
RESULTS: There were 46 men and 18 women included in the study. Mean age was 58.3 years old, and nearly 
half of them (46.9%) were between 50-59 years old. More than half (58.7%) presented with moderate to a severe 
stroke and mean GFAP serum level was 0.113 ± 0.029 ng/mL. GFAP serum levels had a significant correlation 
with NIHSS after 1 month (p = 0.04, r = 0.259). 
CONCLUSION: There is a significant correlation between GFAP serum levels with stroke severity scale after 1 
month of stroke onset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
As the third leading cause of morbidity and 
disability in the world, the global burden of stroke-
affected all populations throughout countries 
worldwide [1], [2]. In Indonesia stroke is the leading 
cause of death, with a prevalence of 12 per mil. It is 
estimated that the tendency of increasing prevalence 
would also increase the burden of disease, and further 
decrease the nation’s productivity and economic 
capacity [3], [4], [5]. 
GFAP is a specific intermediate filament type 
III produce by astrocytes. In brain injury, astrocytes 
will release GFAP which then penetrates the 
cerebrospinal fluids (CSF) and blood stream. 
Coherently, the extent of infarct volume should 
correlate to GFAP level. GFAP concentration in serum 
is higher in haemorrhagic stroke compared to 
ischemic stroke. Several studies show that an 
increase in GFAP serum concentrations in acute 
stroke shows an unfavourable outcome [1], [6]. 
The difference between populations and 
stroke severity may produce a different result. Hence 
we sought to determine whether GFAP serum 
concentrations in 72 hours of onset would correlate 
with patient’s neurological deficit at that time, day 7 
and 1 month later.  
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Methods 
 
Patients with acute ischemic stroke, the onset 
of ≤ 72 hours were included in the study. Patient’s 
demographic data and stroke risk factors were 
documented. Neurologic deficits were assessed using 
The National Institute of Health Stroke Scale (NIHSS) 
at that time and followed up after 1 month of onset. All 
patients were treated with antiplatelet and statins 
along with early rehabilitation. Patients with a history 
of previous stroke, traumatic brain injury, brain 
tumour, infection, degenerative brain disease, liver 
failure, kidney failure, chronic heart disease and acute 
myocardial infarct were excluded. Patients receiving 
thrombolytic were also excluded. 
All patients underwent brain MRI 1.5T to 
confirm ischemic stroke. A blood sample was taken ≤ 
72 hours of onset. As much as 3 cc were drawn and 
inserted in a tube. The tube was kept at room 
temperature for 30-45 minutes, then centrifuged 3000 
rpm for 15 minutes. Blood was then divided into 3 
sample cup as much as 0.3 cc each. Sample cup was 
labelled then stored at -70°C. All sample cups were 
sent to the laboratory using a cool box with dry ice. 
GFAP biomarker was measured using Quantitative 
Enzyme Immunoassay (ELISA) method. 
  
Data analysis 
Data were collected using the provided 
research form. Data was then edited, coded and 
organised using SPSS version 20.0 software. 
Statistical analysis was done using the statistic test 
which appropriates with research variables 
measurement scale. Spearman correlation test was 
used to test the correlation between these 2 variables. 
The significant level of this analysis was set at 5%. 
 
Ethical clearance 
Ethical clearance was obtained from the 
Mochtar Riady Institute for Nanotechnology Ethics 
Committee Number 072/MRIN-EC/08/2014. 
 
 
Results 
 
As much as 64 patients were included in the 
study. Mean age was 58.8 years old with male 
predominance (62%). Most patients were between 50-
59 years old. Almost all patients have hypertension 
(93.75%), and most came with Lacunar anterior 
circulation infarct (LACI). Over half of the patients had 
moderate NIHSS (Table 1). 
 
Table 1: Demographic data and patients’ characteristics 
Variable N % 
Gender   
Male 46 71.88 
Female 18 28.13 
Age group (years)   
30-39 1 1.56 
40-49 10 15.63 
50-59 30 46.88 
60-69 10 15.63 
70-79 11 17.19 
80-89 2 3.13 
BMI   
Underweight 1 1.56 
Normal 36 56.25 
Overweight 20 31.25 
Obese 7 10.94 
Diabetes   
Yes 17 26.56 
No 47 73.44 
Hypertension   
Yes 60 93.75 
No 4 6.25 
Dyslipidemia   
Yes 53 82.81 
No 11 17.19 
Smoking   
Yes 17 26.56 
No 47 73.44 
Atrial fibrillation   
Yes 5 7.81 
No 59 92.19 
Type of Stroke (Bamford)    
LACI 49 76.56 
Non-LACI 15 23.43 
 
Stroke severity was assessed using the 
NIHSS, categorised as mild if NIHSS was 0-3, 
moderate if NIHHS was 4-15 and severe if NIHSS 
was 16-42. NIHSS was scored in 72 onsets, at day 7 
of onset, and after 30 days of onset, as seen in Table 
2. Mean NIHSS is shown in Figure 1. 
 
Figure 1: Mean NIHSS on 72 hours of onset, day 7 and day 30 
 
In 72 hours of stroke onset, serum GFAP was 
sampled in 64 patients, and the mean value was 
0.113 ± 0.029 (0.011-0.248) ng/L.  
Table 2: Stroke severity scale of patients using NIHSS 
Stroke Severity Scale n Percentage (%) 
NIHSS 72 hours 
  
 
Mild (0-3) 24 37.5 
 
Moderate (4-15) 38 59.4 
 
Severe (16-42) 2 3.1 
NIHSS day 7 
  
 
Mild (0-3) 35 54.7 
 
Moderate (4-15) 28 43.8 
 
Severe (16-42) 1 1.6 
NIHSS day 30 
  
 
Mild (0-3) 55 85.9 
 
Moderate (4-15) 9 14.1 
 
Severe (16-42) 0 0 
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Spearman correlation test was utilised to see 
if there was a correlation between GFAP serum 
concentration in the acute phase and stroke severity 
scale at 72 hours, day 7, and day 30. GFAP serum 
had a positive correlation to stroke severity on 72 
hours, day 7 and day 30. This correlation seems to be 
more intense towards day 30 (Table 3). 
Table 3: Correlation between GFAP serum concentration and 
stroke severity 
 NIHSS 72 hours NIHSS day 7 NIHSS day 30 
r 0.223 0.255 0.266 
p 0.076 0.042 0.034 
 
To analyse the relevancy of GFAP level in the 
acute phase and stroke severity, we set a cut-off 
value using Roc analysis (area under the curve/ 
AUC), (Table 4). 
Table 4: Roc Analysis of GFAP serum level and NIHSS 
Stroke Severity Cut Off Sen (%) Spe (%) LR+ LR- AUC 
NIHSS 72 
hours ≥ 0.112 55.26 72.7 2.02 0.61 0.65 
NIHSS day 7 ≥ 0.112 68 69.7 2.24 0.46 0.71 
NIHSS day 30 ≥ 0.114 66.67 74 2.56 0.45 0.66 
  
By obtaining this cut-off, GFAP serum level 
was categorised into low and high. We perform 
another correlation test using Spearman to know the 
correlation between the level of GFAP and 
categorised stroke severity. After the stroke severity 
was categorised as mild and moderate/severe, the 
relation is most robust when compared to day 7 
(Table 5). 
Table 5: Correlation between categorised level of GFAP and 
categorised stroke severity 
  Stroke Severity Correlation 
  Mild Moderate-Severe r p 
72 hours < 0.112 19 18 0.071 0.018 
 ≥ 0.112 6 21   
Day 7 < 0.112 25 12 0.303 0.015 
 ≥ 0.112 10 17   
Day 30 < 0.114 40 5 0.131 0.303 
 ≥ 0.114 15 4   
 
The level of GFAP serum shows a positive 
correlation towards stroke severity in 72 hours and 
day 7. However, this correlation was not seen in 
NIHSS day 30. 
 
 
Discussion 
 
Astrocyte is a special glial cell which is 
abundant and reacted to brain insult known as 
“reactive astrogliosis”, which act as a sign of structural 
damage [7]. 
In the event of ischemic stroke, oxygen levels 
in brain tissue decreased. This disrupts the viability of 
surrounding tissues, damaging neurons, astrocytes 
and blood-brain barrier. The destruction of astrocytes 
releases GFAP protein which is an astrocyte’s 
cytoskeleton. GFAP enters the blood vessels through 
a damaged blood-brain barrier [8].
 
GFAP is a part of 
astrocyte cytoskeletons and has big molecular size 
(40-54 kDa). The more extended the damage, the 
higher the elevation of serum GFAP. The higher 
concentration is commonly seen in intracerebral 
haemorrhage rather than ischemic stroke [9]. In this 
study, we sought to understand the pathomechanism 
of brain injury in acute stroke by analysing GFAP – a 
product of astrocyte and looking into stroke severity 
after 1 month of onset. 
This study consists of 64 acute stroke 
patients, and most frequent risk factors were 
hypertension, dyslipidemia, and smoking. This finding 
has a similar profile compared with the previous study 
by Kusuma in 2009 and Mihardja in 2016. Most 
strokes have the clinical syndrome of LACI (Lacunar 
Cerebral Infarct) as seen in Table 1 [3], [10]. Most of 
the patients came with moderate stroke severity 
(Table 2). During follow up, the percentage of 
moderate and severe stroke decreased, and by day 
30, the majority of patients had a mild stroke (Figure 
1). Traditionally, lacunar infarcts were considered to 
have a more favourable outcome. However, in 2003 
Norrving in his research found that the case fatality 
rate increased at long term follow up. Patients with 
lacunar infarct also had an increased risk for 
recurrence and high risks for cognitive impairment and 
dementia. Silent lacunae also double the risk of 
dementia in the elderly. And for that, lacunar infarct 
should be considered an ominous marker of small-
vessel disease of the brain. In this study, follow up 
was carried out until day 30 and it may be equitable 
that we acquire a decent outcome [11], [12].
 
In less than 72 hours, GFAP serum 
concentration was 0.113 ± 0.029 ng/L. This finding 
does not differ much from a study by Wunderlich in 
2006, which found a mean GFAP of 0.15 ng/mL [11]. 
Hermann in 2000 discovered that the highest level of 
GFAP was on day 4, whereas Wunderlich found that 
on 48 hours of stroke onset GFAP was at its highest, 
and stayed high until day 5 [13], [14].
 
Several studies have tried to obtain GFAP 
cutoff in various brain injury. Ren in 2016 found that 
0.34 ng/ml is a cutoff to differentiate between ischemic 
and hemorrhagic stroke, and also associated with 
stroke severity [1]. Nylen in 2007 uses 0.15 ng/mL as 
a cutoff to predict unfavourable outcome in 
aneurysmal subarachnoid haemorrhage [15]. 
Okonkwo in 2013 obtained optimal cutoff of 0.68 
ng/mL to distinguish the presence and severity of CT 
Scan findings in traumatic brain injury patients [16].
 
In this study, we obtain a cut off value for 
GFAP using Roc analysis and then analyse stroke 
severity using those cut-offs (Table 4 and Table 5). 
GFAP cut-off for 72 hours and day 7 was 0.112 and at 
day 30 was 0.114. This cutoff is relatively lower than 
the previous study; however, seems reasonable 
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considering the different research design and cases.  
After we categorised the level of GFAP, it 
shows a positive correlation with stroke severity at 72 
hours and on day 7. This shows that in acute stroke 
until day 7, serum GFAP of 0.112 ng/mL and more is 
considered high, and correlates with more severe 
stroke on 72 hours until day 7. 
Spearman test shows a positive correlation 
between serum GFAP at less than 72 hours and 
stroke severity on day 7 and day 30. The correlation 
seems to be more substantial towards day 30 (Table 
3). This finding was consistent with Wunderlich who 
acclaimed that serum GFAP 96 hours after stroke 
onset correlates with clinical severity 3 months later 
[13]. This finding shows that patients with higher 
serum GFAP does not necessarily have higher stroke 
severity on admission, but shows more severe stroke 
on follow up at day 7 and day 30. The more intense 
correlation towards day 30 made us believe that if we 
had extended the follow up to a much longer period, 
the correlation might have been more robust. 
In conclusion, GFAP serum concentration in 
acute ischemic stroke has a positive correlation with 
clinical severity stroke scale in acute settings (< 72 
hours), day 7, and day 30. GFAP could be utilised as 
a predictor of clinical outcome 1 month after stroke. 
We propose a GFAP serum level of 0.112 ng/mL as a 
cut off for high-level GFAP serum concentration, 
which might predict stroke severity until day 7.  
There are some limitations to this study. The 
sample size was rather small, and GFAP 
concentration was measured only once at the acute 
phase. Stroke severity was also analysed using only 
one stroke scale, without integrating cognitive 
assessment. Follow up was done only 30 days after, 
which may reveal a different result if it had been 
longer. 
We expect other studies in the future that 
included all the aspects of our limitations and 
hopefully broaden our understanding of GFAP in 
stroke cases. 
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